|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/06/18 Allscripts Healthcare Soluti… Inc 10-Q 6/30/18 106:22M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.36M
2: EX-2.1 Plan of Acquisition, Reorganization, Arrangement, HTML 501K
Liquidation or Succession
3: EX-2.2 Plan of Acquisition, Reorganization, Arrangement, HTML 524K
Liquidation or Succession
4: EX-31.1 Certification -- §302 - SOA'02 HTML 38K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 38K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 33K
13: R1 Document and Entity Information HTML 52K
14: R2 Consolidated Balance Sheets (Unaudited) HTML 161K
15: R3 Consolidated Balance Sheets (Unaudited) HTML 54K
(Parenthetical)
16: R4 Consolidated Statements of Operations (Unaudited) HTML 131K
17: R5 Consolidated Statements of Comprehensive Income HTML 63K
(Loss) (Unaudited)
18: R6 Consolidated Statements of Cash Flows (Unaudited) HTML 127K
19: R7 Basis of Presentation and Significant Accounting HTML 49K
Policies
20: R8 Revenue from Contracts with Customers HTML 611K
21: R9 Business Combinations HTML 172K
22: R10 Fair Value Measurements and Long-term Investments HTML 183K
23: R11 Stockholders' Equity HTML 142K
24: R12 Earnings (Loss) Per Share HTML 249K
25: R13 Goodwill and Intangible Assets HTML 262K
26: R14 Debt HTML 309K
27: R15 Income Taxes HTML 68K
28: R16 Derivative Financial Instruments HTML 212K
29: R17 Other Comprehensive Income HTML 365K
30: R18 Contingencies HTML 40K
31: R19 Discontinued Operations HTML 137K
32: R20 Business Segments HTML 196K
33: R21 Supplemental Disclosures HTML 80K
34: R22 Subsequent Events HTML 38K
35: R23 Basis of Presentation and Significant Accounting HTML 83K
Policies (Policies)
36: R24 Revenue from Contracts with Customers (Tables) HTML 575K
37: R25 Business Combinations (Tables) HTML 161K
38: R26 Fair Value Measurements and Long-term Investments HTML 179K
(Tables)
39: R27 Stockholders' Equity (Tables) HTML 135K
40: R28 Earnings (Loss) Per Share (Tables) HTML 251K
41: R29 Goodwill and Intangible Assets (Tables) HTML 257K
42: R30 Debt (Tables) HTML 309K
43: R31 Income Taxes (Tables) HTML 60K
44: R32 Derivative Financial Instruments (Tables) HTML 211K
45: R33 Other Comprehensive Income (Tables) HTML 366K
46: R34 Discontinued Operations (Tables) HTML 140K
47: R35 Business Segments (Tables) HTML 188K
48: R36 Supplemental Disclosures (Tables) HTML 79K
49: R37 Basis of Presentation and Significant Accounting HTML 38K
Policies - Additional Information (Detail)
50: R38 Revenue from Contracts with Customers - Additional HTML 84K
Information (Detail)
51: R39 Revenue from Contracts with Customers - Impact of HTML 66K
Adoption on Previously Reported Condensed
Consolidated Balance Sheet (Detail)
52: R40 Revenue from Contracts with Customers - Schedule HTML 67K
of Comparison Between Reported Statements to
Pro-forma Amounts in Effect of Previous Guidance -
Consolidated Balance Sheet (Detail)
53: R41 Revenue from Contracts with Customers - Schedule HTML 78K
of Comparison Between Reported Statements to
Pro-forma Amounts in Effect of Previous Guidance -
Statement of Operations (Detail)
54: R42 Revenue from Contract with Customer - Summary of HTML 43K
Revenue Regognized Related to Various Performance
Obligations and Elected accounting Expedients
(Detail)
55: R43 Revenue from Contracts with Customers - Summary of HTML 71K
Revenue by Type and Nature of Revenue Stream by
Reportable Segments (Detail)
56: R44 Business Combinations - Agreement to Acquire HTML 60K
Health Grid - Additional Information (Detail)
57: R45 Schedule of Consideration Transaction (Detail) HTML 54K
58: R46 Assets Acquired and Liabilities Assumed (Detail) HTML 72K
59: R47 Acquired Intangible Assets Amortization (Detail) HTML 56K
60: R48 Business Combinations - Acquisition of Practice HTML 50K
Fusion, Inc - Additional Information (Detail)
61: R49 Business Combinations - Other Acquisitions and HTML 120K
Divestiture - Additional Information (Detail)
62: R50 Business Combinations - Acquisition of DeVero - HTML 40K
Additional Information (Detail)
63: R51 Business Combinations - Acquisition of the HTML 39K
Patient/Provider Engagement Solutions Business
from NantHealth, Inc. - Additional Information
(Detail)
64: R52 Business Combinations and Other Investments - HTML 54K
Acquisition of the Enterprise Information
Solutions Business from McKesson Corporation -
Additional Information (Detail)
65: R53 Business Combinations - Formation of Joint HTML 42K
Business Entity and Acquisition of Netsmart, Inc -
Additional Information (Detail)
66: R54 Pro forma Results (Detail) HTML 38K
67: R55 Fair Value Measurements and Long-term Investments HTML 45K
- Additional Information (Detail)
68: R56 Summary of Financial Assets and Liabilities HTML 72K
Measured at Fair Value on Recurring Basis (Detail)
69: R57 Summary of Changes in Assets and Liabilities HTML 40K
Measured at Fair Value on Recurring Basis (Detail)
70: R58 Summary of Long-term Equity Investments Included HTML 51K
in Other Assets (Detail)
71: R59 Stockholders' Equity - Additional Information HTML 64K
(Detail)
72: R60 Stock-Based Compensation Expense (Benefit) HTML 47K
(Detail)
73: R61 Stock-Based Awards Granted (Detail) HTML 44K
74: R62 Calculations of Earnings (Loss) Per Share (Detail) HTML 95K
75: R63 Anti-Dilutive Stock Options, Restricted Stock Unit HTML 34K
Awards and Warrants Excluded from Computation of
Diluted Earnings (Loss) Per Share (Detail)
76: R64 Goodwill and Intangible Assets (Detail) HTML 50K
77: R65 Changes in Carrying Amount of Goodwill (Detail) HTML 84K
78: R66 Goodwill and Intangible Assets - Additional HTML 64K
Information (Detail)
79: R67 Debt Outstanding Excluding Capital Leases (Detail) HTML 66K
80: R68 Interest Expense (Detail) HTML 46K
81: R69 Interest Expense Related to 1.25% Notes (Detail) HTML 39K
82: R70 Debt - Additional Information (Detail) HTML 138K
83: R71 Summary of Future Debt Payment Obligations HTML 78K
(Detail)
84: R72 Summary of Future Debt Payment Obligations HTML 34K
(Parenthetical) (Detail)
85: R73 Effective Tax Rates (Detail) HTML 40K
86: R74 Income Taxes - Additional Information (Detail) HTML 65K
87: R75 Fair Value and Balance Sheet Locations - (Detail) HTML 53K
88: R76 Derivative Financial Instruments - Additional HTML 67K
Information (Detail)
89: R77 Derivatives Instruments Designated as Cash Flow HTML 46K
Hedges - (Detail)
90: R78 Net Impact of Changes in Fair Value of Call Option HTML 39K
and Embedded Cash Conversion Option - (Detail)
91: R79 Components of Accumulated Other Comprehensive Loss HTML 61K
(Detail)
92: R80 Components of Accumulated Other Comprehensive Loss HTML 38K
(Parenthetical) (Detail)
93: R81 Income Tax Effects Related to Components of Other HTML 115K
Comprehensive Income (Loss) (Detail)
94: R82 Income Tax Effects Related to Components of Other HTML 34K
Comprehensive Income (Loss) (Parenthetical)
(Detail)
95: R83 Contingencies - Additional Information (Detail) HTML 32K
96: R84 Discontinued Operations - Additional Information HTML 40K
(Detail)
97: R85 Summary of Major Classes of Assets and Liabilities HTML 66K
of Discontinued Operations (Detail)
98: R86 Summary of Major Classes of Line Items HTML 69K
Constituting Income (Loss) of Discontinued
Operations (Detail)
99: R87 Business Segments - Additional Information HTML 44K
(Detail)
100: R88 Revenues and Income from Operations Related to HTML 55K
Segment Within Reconciliation to Consolidated
Amounts (Detail)
101: R89 Supplemental Disclosures - Additional Information HTML 40K
(Detail)
102: R90 Supplemental Disclosures (Detail) HTML 55K
103: R91 Subsequent Events - Additional Information HTML 51K
(Detail)
105: XML IDEA XML File -- Filing Summary XML 202K
104: EXCEL IDEA Workbook of Financial Reports XLSX 129K
7: EX-101.INS XBRL Instance -- mdrx-20180630 XML 7.02M
9: EX-101.CAL XBRL Calculations -- mdrx-20180630_cal XML 316K
10: EX-101.DEF XBRL Definitions -- mdrx-20180630_def XML 1.01M
11: EX-101.LAB XBRL Labels -- mdrx-20180630_lab XML 1.55M
12: EX-101.PRE XBRL Presentations -- mdrx-20180630_pre XML 1.48M
8: EX-101.SCH XBRL Schema -- mdrx-20180630 XSD 243K
106: ZIP XBRL Zipped Folder -- 0001564590-18-019295-xbrl Zip 310K
Exhibit 32.1
The following statement is being made to the Securities and Exchange Commission solely for purposes of Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), which carries with it certain criminal penalties in the event of a knowing or willful misrepresentation.
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Re: Allscripts Healthcare Solutions, Inc.
Ladies and Gentlemen:
In accordance with the requirements of Section 906 of the Sarbanes-Oxley Act of 2002 (18 USC 1350), each of the undersigned hereby certifies that:
(i) this Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, which this statement accompanies, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
(ii) the information contained in this Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, fairly presents, in all material respects, the financial condition and results of operations of Allscripts Healthcare Solutions, Inc.
Dated as of this 3rd day of August, 2018.
|
/s/ Paul M. Black |
|
|
|
/s/ Dennis M. Olis |
|
Chief Executive Officer |
|
|
|
Chief Financial Officer |
A signed original of this written statement required by Section 906 has been provided to Allscripts Healthcare Solutions, Inc. and will be retained by Allscripts Healthcare Solutions, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/6/18 | None on these Dates | ||
| For Period end: | 6/30/18 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/29/22 Veradigm Inc. 10-K/A 12/31/21 12:4M Donnelley … Solutions/FA 2/25/22 Veradigm Inc. 10-K 12/31/21 150:28M Donnelley … Solutions/FA 2/26/21 Veradigm Inc. 10-K 12/31/20 165:35M ActiveDisclosure/FA |